Trials / Completed
CompletedNCT02626013
Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece
A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel (ABRAXANE®) Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With Metastatic Breast Cancer in Greece. The 'ABReast' Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 156 (actual)
- Sponsor
- Genesis Pharma S.A. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-interventional study aims at assessing the impact of nab-paclitaxel on the clinical outcomes and the health-related QoL (HRQoL) of this heavily burdened and difficult-to-treat population. Notably, the data generated in the context of this study will serve as complementary evidence to that of the tightly and strictly controlled pre-registration clinical trial setting, which is of essential importance especially in patient populations with diseases of complex and heterogeneous biology, such as breast cancer.
Conditions
Timeline
- Start date
- 2016-04-12
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
- First posted
- 2015-12-10
- Last updated
- 2020-11-30
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT02626013. Inclusion in this directory is not an endorsement.